Topical 0.1% tacrolimus for the treatment of discoid lupus erythematosus and pemphigus erythematosus in dogs.
Topical 0.1% tacrolimus was used for treatment of localized lesions associated with 10 cases of discoid lupus erythematosus (DLE) and two cases of pemphigus erythematosus (PE) either as a sole therapy (n=2) or as an adjunctive treatment (n=10). Eight of 10 dogs with DLE and both dogs with PE were improved following 8 weeks of topical application. In six of the eight dogs that improved, other medications were discontinued. No adverse effects in clinical or laboratory parameters were noted throughout the study.
Griffies
Joel D
JD
Animal Dermatology Clinic, Tustin, California 92780, USA.
Mendelsohn
Colleen L
CL
Rosenkrantz
Wayne S
WS
Muse
Rusty
R
Boord
Mona J
MJ
Griffin
Craig E
CE
D000287:Administration, Topical; D000818:Animals; D004283:Dog Diseases / Q000188:drug therapy* / Q000473:pathology; D004285:Dogs; D005260:Female; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D008179:Lupus Erythematosus, Discoid / Q000188:drug therapy / Q000473:pathology / Q000662:veterinary*; D008297:Male; D010392:Pemphigus / Q000188:drug therapy / Q000473:pathology / Q000662:veterinary*; D016559:Tacrolimus / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome
D007166:Immunosuppressive Agents; D016559:Tacrolimus